FDA Lax in Monitoring Drug Trials

Clinical trials for new drugs receive scant FDA attention according to a recent report. In fact, the FDA only inspected one out of 100 trial sites. These issues affect the safety and efficacy of new drugs coming to the market. Part of the issue concerns lack of resources the FDA can utilize to properly perform inspections and monitoring of new pharmaceuticals.